产品
编 号：F751216
分子式：C22H22FN5O3
分子量：423.44
分子式：C22H22FN5O3
分子量：423.44
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2311863-36-0
产品详情
生物活性：
TRPC6-IN-3 (compound 17) is a potent, orally active transient receptor potential C6 ion channel (TRPC6) inhibitor. TRPC6-IN-3 modulates not only intracellular calcium concentration, but also membrane potential by modulating the flux of cations including calcium and sodium ions. TRPC6-IN-3 can be used in research of respiratory system.
体内研究：
TRPC6-IN-3 (compound 17; 1-10 mg/kg; p.o.; orally 12 h and 2 h before LPS challenge; LPS-induced mice) inhibits LPS-induced vascular leakage and inhibits accumulation of Broncho-Alveolar-Lavage protein (BALF protein) in a mouse model.TRPC6-IN-3 (3 mg/kg; p.o.; daily, for 4 d; H1N1-induced mice) reduces H1N1-induced vascular leakage in a mouse model.Animal Model:LPS-induced mice
Dosage:1, 3, and 10 mg/kg
Administration:Oral administration; orally 12 h and 2 h before LPS challenge
Result:Reduced BALF protein concentration of 56 % at 3 mg/kg and 62 % at 10 mg/kg.
Animal Model:H1N1-induced mice
Dosage:3 mg/kg
Administration:Oral administration; daily, for 4 days
Result:Inhibited Evans blue extravasation from the blood to the BALF and reduced BALF Evans blue by 24 % at 3 mg/kg.
TRPC6-IN-3 (compound 17) is a potent, orally active transient receptor potential C6 ion channel (TRPC6) inhibitor. TRPC6-IN-3 modulates not only intracellular calcium concentration, but also membrane potential by modulating the flux of cations including calcium and sodium ions. TRPC6-IN-3 can be used in research of respiratory system.
体内研究：
TRPC6-IN-3 (compound 17; 1-10 mg/kg; p.o.; orally 12 h and 2 h before LPS challenge; LPS-induced mice) inhibits LPS-induced vascular leakage and inhibits accumulation of Broncho-Alveolar-Lavage protein (BALF protein) in a mouse model.TRPC6-IN-3 (3 mg/kg; p.o.; daily, for 4 d; H1N1-induced mice) reduces H1N1-induced vascular leakage in a mouse model.Animal Model:LPS-induced mice
Dosage:1, 3, and 10 mg/kg
Administration:Oral administration; orally 12 h and 2 h before LPS challenge
Result:Reduced BALF protein concentration of 56 % at 3 mg/kg and 62 % at 10 mg/kg.
Animal Model:H1N1-induced mice
Dosage:3 mg/kg
Administration:Oral administration; daily, for 4 days
Result:Inhibited Evans blue extravasation from the blood to the BALF and reduced BALF Evans blue by 24 % at 3 mg/kg.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备